Concepedia

Daniel M. Camac

DM

Statistics

Publications

17

Citations

656

H-Index

15

Active since

1992

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bristol-Myers Squibb (Sweden)

Biocon (India)

Lexicon Pharmaceuticals (United States)

Daniel M. Camac is an author at Bristol-Myers Squibb (United States) specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

1992–2022

17

Publications

17

Tetraphilin: a four-helix proton channel built on a tetraphenylporphyrin framework

Karin S. Åkerfeldt, Ronald M. Kim, Daniel M. Camac et al. · Journal of the American Chemical Society · 1992 · 151 citations

, , +11

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Robert G. Gentles, Min Ding, John A. Bender et al. · Journal of Medicinal Chemistry · 2014 · 100 citations · Full text

, , +17

Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis

Joseph B. Santella, Daniel S. Gardner, John V. Duncia et al. · Journal of Medicinal Chemistry · 2014 · 55 citations · Full text

, , +7

Acyl Guanidine Inhibitors of β-Secretase (BACE-1): Optimization of a Micromolar Hit to a Nanomolar Lead via Iterative Solid- and Solution-Phase Library Synthesis

Samuel W. Gerritz, Weixu Zhai, Shuhao Shi et al. · Journal of Medicinal Chemistry · 2012 · 50 citations · Full text

, , +17

Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

Xiaofan Zheng, Thomas W. Hudyma, Scott Martin et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 42 citations

, , +13

1–5 of 17